GD2/B7H3 CAR T-cell therapy(Yake Biotechnology)

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameGD2/B7H3 CAR T-cell therapy(Yake Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-GD2 +[4] 
TargetsDisialoganglioside GD2CD276 antigen
Therapy Area/IndicationsNeuroblastomaDesmoplastic Small Round Cell Tumor
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdSun Yat-Sen University
Inactive CompaniesN/A
Active IndicationsNeuroblastomaDesmoplastic Small Round Cell Tumor
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A